DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC - Trial NCT06364917
Access comprehensive clinical trial information for NCT06364917 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Alabama at Birmingham
Timeline & Enrollment
Phase 2
Oct 31, 2024
Jun 01, 2027
Primary Outcome
Rate of Molecular Response in Patients with PD-L1 Negative Advanced NSCLC Treated with Dual vs. Single ICB Plus CT Regimens
Summary
The purpose of this study, known as DISCERN, is to compare two different treatments for a
 type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker
 known as PD-L1. This study will help us understand if using two types of immune therapy
 together with chemotherapy is better than using one type of immune therapy with chemotherapy.
 We're doing this by looking at changes in the subject's cancer's DNA in the blood after
 starting treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364917
Non-Device Trial